Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Virax Biolabs Group Limited's Competitiveness

Name: Virax Biolabs Group Limited Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Virax Biolabs Group Limited (VRAX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q4 2024

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/VRAX/competitors                    

                        https://api.csimarket.com/api/v1/companies/VRAX/relationships                    

                        https://api.csimarket.com/api/v1/companies/VRAX/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Virax Biolabs Group Limited's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Virax Biolabs Group Limited	-	-	-	-
High-Confidence Competitors (3)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

VRAX Stock Performance relative to its Competitors

VRAX Competitors (weighted) Percent change over the selected range

Virax Biolabs Group Limited's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

High-Confidence
(1 of 3)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Virax Biolabs Group Limited	272.00 %	Outperformed
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (3)	40.4%	63.2%
Similar-Size Competitors (0)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Virax Biolabs Group Limited's competitor groups requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

VRAX Stock Performance relative to High-Confidence Competitors

VRAX High-Confidence Competitors (equal-weighted, 4) Percent change over the selected range

Virax Biolabs Group Limited's Comment on Competition and Industry Peers

The Company operates in competitive markets including immune profiling, research-use immune reagents, and in vitro diagnostics (IVD). Its competitors include established diagnostic companies, biotechnology firms, research reagent suppliers, contract research organizations, and emerging technology companies, many of which have greater financial, technical, regulatory, manufacturing, sales, and marketing resources. The Company is developing ViraxImmune™, a T cell immune profiling and in vitro diagnostic platform targeting post-acute infection syndromes such as Long COVID, ME/CFS, and PTLD.

Competitor data is not yet available for Virax Biolabs Group Limited.

Virax Biolabs Group Limited's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
Qiagen N.V.	Named by the company	85%	2022 to 2026	3
Abbott Laboratories	Named by the company	85%	2022 to 2026	3
Roche Holding AG	Named by the company	85%	2022 to 2026	3
Adaptive Biotechnologies Corporation	Named by the company	85%	2022 to 2026	3

Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Virax Biolabs Group Limited's named competitors require a Commercial License.

Unlock Commercial Access

Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.